The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Brexucabtagene autoleucel receives FDA approval for the treatment of relapsed/refractory mantle cell lymphoma

Jul 28, 2020

On July 24, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to brexucabtagene autoleucel (formerly KTE-X19), for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). 1,2

Brexucabtagene autoleucel is a chimeric antigen receptor (CAR) T-cell therapy targeting the CD19 antigen on the surface of lymphoma cells. The FDA approval, that follows a priority review and FDA breakthrough therapy designation, was based on data from the ongoingZUMA-2 trial in patients with R/R MCL who had previously received anthracycline- or bendamustine-containing chemotherapy, an anti-CD20 antibody therapy, and a Bruton tyrosine kinase inhibitor. Results demonstrated an objective response rate of 87% and a complete response rate of 62%. 1,2

In the trial, among patients evaluable for safety (n = 82), 91% experienced cytokine release syndrome (CRS) including 18% with ≥ Grade 3 CRS, and 81% experienced neurologic events including 37% with ≥ Grade 3. Due to the risk of CRS and neurologic toxicities, brexucabtagene autoleucel is only available through a restricted program under a risk evaluation and mitigation strategy . 1

A manufacturing success rate of 96% was reported in the ZUMA-2 trial, with a median manufacturing time of 15 days from leukapheresis to product delivery.

Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) will be a certified treatment center for the therapy. 2

Brexucabtagene autoleucel is under review in the European Union, and it is under investigation in phase I/II trials involving patients with acute lymphoblastic leukemia ( NCT02614066 ) and chronic lymphocytic leukemia ( NCT03624036 ). 1

  1. BusinessWire. U.S. FDA approves Kite’s Tecartus™, the first and only CAR T treatment for relapsed or refractory mantle cell lymphoma. https://www.businesswire.com/news/home/20200724005428/en/. Published Jul 24, 2020. Accessed Jul 27, 2020.
  2. Dana-Farber Cancer Institute. Dana-Farber to offer first CAR T-cell therapy for mantle cell lymphoma following FDA approval. https://www.dana-farber.org/newsroom/news-releases/2020/dana-farber-to-offer-first-car-t-cell-therapy-for-mantle-cell-lymphoma-following-fda-approval/. Published Jul 24, 2020. Accessed Jul 27, 2020.